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New blood vessel formation (angiogenesis) is essential forthe processes of tumor growth, invasion, and metastatic
dissemination,1 and agents that inhibit this pathway, such as
bevacizumab, have proven anticancer activity.2 Interactions
between tumor- and stroma-produced vascular endothelial
growth factor (VEGF) ligands (particularly VEGF-A) and
receptors (particularly VEGF receptor [VEGFR] 2) are cen-
tral to angiogenesis and vessel permeability.3 VEGF-A also
interacts with VEGFR1 expressed on endothelial cells, mac-
rophage-lineage cells, and some tumor cells, assisting in
angiogenesis and promoting direct tumor growth, metastasis,
and inflammation.4 VEGFR3 is critical for lymphangiogen-
esis.5 Targeting the VEGF pathway inhibits vasculogenesis
and tumor progression and is also thought to transiently
normalize the tumor vascular supply, resulting in improved
drug delivery when used in combination regimens.6 Drugs
targeting the VEGF pathway7 that were discussed at the 9th
annual targeted therapies meeting in Santa Monica are de-
scribed below.
VEGF Ligand Blockers
Dr. Alan Sandler discussed Bevacizumab (Avastin), a
humanized monoclonal antibody to circulating VEGF iso-
forms thus reducing circulating VEGF to undectectable lev-
els. Two large phase III trials with the compound in combi-
nation with first-line chemotherapy have been presented.
E4599 combined bevacizumab with carboplatin and pacli-
taxel (C  P) and found an improved RR (35% versus 15%),
progression-free survival (PFS, 6.2 versus 4.5 months) and
overall survival (OS, 12.3 versus 10.3 months).2 Bevaci-
zumab increased hematologic toxicities, febrile neutropenia,
hypertension, and proteinuria with 15 treatment-related
deaths including five from pulmonary hemorrhage (PH).
Among predictive markers studied, only low level of inter-
cellular adhesion molecule correlated with better overall and
1-year survival. A European/Canadian phase III (AVAiL)
combination of cisplatin/gemcitabine with 7.5 or 15 mg/kg of
(B) or placebo had no improvement in OS but equivalent
increase in RR and PFS at both doses (34.1/30.4 versus
20.1%) and (6.7/6.5 versus 6.1 months), when compared with
placebo.8 Safety data were similar for both doses. In newer
data, no intracranial hemorrhage occurred in 83 patients with
pretreated brain metastases while on the ATLAS and PASS-
PORT studies.9 Retrospective evaluation identified baseline
cavitation but not central tumor location to be associated with
severe PH in patients treated with C  P  B.10 ECOG 1505
is a phase III randomized trial of bevacizumab versus placebo
with standard chemotherapy doublets in the adjuvant setting.
Dr. Natasha Leighl discussed Aflibercept (VEGF Trap/
AVE0005) a recombinant fusion protein of extracellular do-
main portions from human VEGFR1 and 2 combined with the
Fc of human IgG. This acts as a soluble VEGF receptor
“trapping” VEGF from the circulation. Some single agent
activity at 4 mg/kg every 2 weeks was seen, with expected
VEGF related toxicity including two of 96 patients with PH
in a phase II study in platinum- and erlotinib-resistant ade-
nocarcinoma. Ongoing trials include a second-line phase III
combination with docetaxel and a phase I/II combination with
pemetrexed and cisplatin.
VEGFR2 Receptor Blockers
Dr. Ross Camidge discussed Ramucirumab (IMC-
1121B), a fully human IgG1 monoclonal antibody, that binds
VEGFR-2 and blocks VEGF ligand binding. The drug was
well tolerated on weekly and biweekly schedules in phase I
trials. Mechanism-related dose-limiting toxicities were hy-
pertension, proteinuria, telangiectasia, and DVT. Patients
who do not have lung cancer were studied in phase I, but
encouraging single agent activity was seen in other malig-
nancies. Ramucirumab is currently in a phase II clinical trial
with C  P.
Dr. Leila Alland discussed Adnectin (CT-322), a fi-
bronectin-based small protein, that blocks VEGFR2 interac-
tion with three of its ligands VEGF (A, C, and D). In phase
I, it was well tolerated at weekly doses of 1 and 2 mg/kg with
manageable VEGF pathway-related toxicity (HTN and pro-
teinuria) and no cutaneous toxicity and no fatigue  G2. A
phase II chemotherapy combination trial is planned.
Oral Small-Molecule Tyrosine Kinase Inhibitors
Dr. Amir Onn discussed Vandetanib (Zactima, ZD6474),
an inhibitor of VEGFR2/3, RET, and less potently of EGFR. In
second-line phase III trials, vandetanib improved PFS and
quality of life in patients on docetaxel (ZODIAC trial) and
improved RR and quality of life but not PFS in patients on
pemetrexed (ZEAL trial). As a single agent, it was equivalent
to standard dose erlotinib on the ZEST trial. The ZEPHYR
study of vandetanib monotherapy versus placebo in patients
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with prior anti-EGFR exposure is ongoing. Most common
toxicities included rash, diarrhea, and hypertension.
Dr. Glenwood Goss discussed Cediranib (Recentin,
AZD 2171) a highly potent daily pan-VEGFR, c-KIT, and
PDGFR inhibitor. The randomized phase II Canadian trial
BR.24 of C  P  cediranib had to be amended to reduce
dose from 45 to 30 mg because of excessive diarrhea, neu-
tropenia, and dehydration. Despite an improvement in OR
from 20 to 41% and a trend toward improvement in PFS, the
study had to be discontinued because of disproportional
increased death rate in the cediranib arm even at the 30 mg
dose (11.5% versus 2% [p  0.002]). All subgroups and
histologies benefited except for patients with 5% wt loss,
poor performance, and low albumin at enrollment. A random-
ized phase II/III trial BR.29 of C P 20 mg/d of cediranib
with preplanned early safety analysis was started.
Dr. Paul Bunn discussed BIBF 1120 a potent triple
inhibitor of VEGFR(1/2/3), fibroblastic growth factor (1/2/3),
and PDGFR(/). Most common toxicities presented in-
cluded nausea, vomiting, diarrhea, increase in liver enzymes
but no hand-foot syndrome, myelosuppression, or HTN. In 57
patients, single agent BIBF 1120 given beyond first line had
3.5% OR, 59% DCR, 12-week PFS, and 38-week OS. Two
phase III trials (LUME-lung 1 and 2) are recruiting for second
line of BIBF 1120 200 mg twice a day with docetaxel or
pemetrexed, respectively.
Dr. Karen Kelly discussed AV-951 a potent highly
selective pan-VEGF (1/2/3) inhibitor with a prolonged half-
life. With 4 weeks on 2 weeks off dosing in phase I, common
G1/2 toxicities were nausea/vomiting, diarrhea, hoarseness,
rash, myalgias, and dose-dependent hypertension. DLTs were
proteinuria, intracranial bleeding, and ataxia at 2 mg and two
cases of reversible transaminitis at 1.5 mg/d. One patient with
NSCLC had prolonged disease stability for 9 months. A phase
Ib/IIa single agent study of 1 to 1.5 mg daily is ongoing.
Dr. Heather Wakelee discussed XL647, a multikinase
inhibitor, with activity against VEGFR-2, HER2, EphB4, and
EGFR. In a phase II first-line trial, patients with known
sensitizing EGFR mutations or clinically favorable character-
istics (Asian, female, and never smokers) received 350 mg
PO daily 5/14 days of XL647 with a 26% partial response
(PR) rate (7/10 EGFRmut []). On phase II trial, patients
with progression after PR or prolonged SD on erlotinib/
gefitinib or with a known T790M mutation received 300 mg
PO daily continuously with 1/39 PR (exon 19 del) and 19 of
39 SDs. Activity was not seen in patients with T790M
mutations. Mostly, G1/2 AEs included diarrhea, rash, fatigue,
nausea, hypertension, anorexia, and reversible QTc prolon-
gation with one patient with pneumonitis.
Dr. Joan Schiller discussed three tyrosine kinase inhib-
itors described below. Axitinib (AG-013736) is a potent
inhibitor of all three VEGF receptors, PDGFR-, and c-Kit.
In a phase II trial, single-agent axitinib gave a PFS of 9.2
months, OS of 14.8 months, and 77.8% 1-year survival in
nine patients treated first line and PFS of 3.8 months, OS of
15.5 months, and 1-year survival of 56.5% in 23 patients
treated beyond first line. Two phase II first-line clinical trials
of chemotherapy with axitinib are ongoing: one comparing
axitinib to bevacizumab together with standard dose of C 
P and continued as maintenance and a second single-arm
study of cisplatinum  gemcitabine and axitinib in patients
with squamous histology.
Sunitinib (Sutent) is a less selective multityrosine ki-
nase inhibitor of VEGF, Kit, FLT3, PDGFR, and Raf. It had
29% SD and 1% PR when used alone continuously in the
second-line phase II trial leading to mPFS of 12 weeks, mOS
of 23.4 weeks and 1-year survival of 20%. Higher response
rates were seen in earlier trials of intermittent dosing. Three
trials are ongoing: phase II CALGB 30704 randomizes pa-
tients to second-line sunitinib or pemetrexed with or without
sunitinib; phase III CALGB 30607 looks at sunitinib main-
tenance after four cycles of chemotherapy; and a third trial
randomizes previously treated patients to erlotinib  sunitinib
(phase III).
Sorafenib (Nexavar) is a less selective multikinase
inhibitor of PDGFR-, Raf, c-Kit, FLT3 and all VEGFRs. In
ESCAPE (a phase III first-line trial with C  P), the addition
of sorafenib did not affect PFS (hazard ratio [HR] 1.0) or OS
(HR 1.16, not significant) in the overall population but had a
detrimental effect on mOS in the squamous histology sub-
group (8.9 versus 13.6 months). In the phase II (E2501)
randomized discontinuation study, 400 mg twice a day of
sorafenib improved PFS rates (after 2 months run in phase of
sorafenib) compared with placebo (3.6 versus 2.0 months,
HR 2.16, p  0.009) with a trend toward improvement in OS
(11.9 versus 9.0 months, HR 1.5, p  0.18). There is an
ongoing phase I study of C  P  Bevacizumab sorafenib,
the phase III NEXUS study of first-line cisplatin, gemcitabine
with sorafenib, or placebo has met its accrual goal, a phase II
second-line pemetrexed  sorafenib is accruing, a phase II
second or third-line erlotinib  sorafenib is accruing, and a
phase III sorafenib versus placebo trial in third/fourth line
setting is in development.
SUMMARY AND FUTURE DIRECTIONS
There is abundant proof of activity of VEGF inhibition
in NSCLC, but overall results seem modest with only small
increases in activity when used in combination with chemo-
therapy and sometimes at the expense of significant toxicity.
Single agent activity may be mostly limited to less selective
tyrosine kinase inhibitors. Because there are subgroups of
patients with dramatic benefit and prolonged disease stability
with VEGF inhibition, it is of high priority to find reliable
biomarkers able to identify them. Future studies are expected
to further clarify the mode of action of VEGF inhibitors and
help select compounds with better benefit to toxicity ratio.
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